The FDA has approved the first treatment that can delay the start of Type 1 diabetes, a disease that can emerge in teenagers.
Under the brand name Tzield, Provention Bio will market the drug in the US. In an investor call on Friday, Provention said the drug would cost between $13,850 and $193,900 for 14 days of treatment. Tepilizumab is expected to be available by the end of the year.
The drug doesn't cure or prevent diabetes. It takes an average of two years for the drug to kick in for some patients, and 11 years for others.
The course of the disease is unaffected by the discovery of the only other treatment for the disease. What is missing is replaced by something else.
Tepilizumab will be used to treat patients at high risk for Type 1 diabetes who have an immune attack on their pancreas and who have not normal blood sugar levels. The drug is used to block T cells from attacking the cells of the pancreas.
Mark S. Anderson is the director of the diabetes center at the University of California, San Francisco. Dr. Anderson has worked for Provention before.
John Buse, a diabetes expert at the University of North Carolina who was not involved in the study, called the approval "really exciting" and said it would "turn the world ofType 1 diabetes on its head."
He said that screening would be a good idea. Medical experts haven't promoted it to detectType 1 diabetes.
No screening test is necessary. Only 4% of the population will be affected by this rare but dire disease, which affects over one million Americans.
Patients with type 1 diabetes emerge in adolescence when they are tired all the time, lose weight, and urinate frequently.
The lives of people with diabetes are completely different. They have to keep their blood sugar under control. They have to figure out how muchinsulin they need every time they eat. They can pass out if they take too much.
Eye disease can lead to blindness, heart disease, and stroke. As soon as five years after diagnosis, there can be problems with blood sugar.
The first immunotherapy for cancer was a breakthrough to a new era of treatment. He thinks that the disease may be halted before it starts.
The new drug isn't a treatment for type 2 diabetes, in which the body doesn't respond to insulin, but rather it's a treatment for a different type of diabetes.
The story of the new treatment dates back to the 1980s and involves determined researchers who pursued the idea as company after company, but then ended up dropping the drug for a number of reasons.
Dr. Herold and Dr. Bluestone spent 20 years trying to keep the drug alive.
According to Dr. Bluestone, scientists were passionate about it. The guys at companies were very passionate about it. It was dropped for a variety of reasons.
Dr. Herold said that he and Dr. Bluestone went to drug companies to beg them to pick up the pieces.
At one point, Dr. Bluestone made a clinical batches of the drug in the lab after taking the antibody. Dr. Herold tested it in a small group of people.
The treatment extended the period in which they made some blood thinners.
A new type of study was proposed by Dr. Herold. People who were at high risk of diabetes would be treated. Dr. Bluestone said it was a big move. There aren't many drugs given before a diagnosis.
The researchers worked with a group of trial sites to find those people. The group has a new chairman. TrialNet investigators screened 200,000 people who were immediate family members of people with Type 1 diabetes to see if they had any signs of an immune attack.
A study published in the New England Journal of Medicine resulted in Thursday's approval.
The challenge will be finding people who can benefit from the drug. Only people with immediate relatives who have diabetes can be screened.
The N.I.H. funded the trial that led to the drug's approval, and the group that advocates for people with Type 1 diabetes wants the tests to be included in routine care.
Most families think a diagnosis is a bolt out of the blue. He said that most patients are very sick when they are diagnosed.
In parts of Colorado and in Germany, the group has done blood tests. The foundation funded the at- home test. The doctor said that they want the offices of the children to do it.
Another opportunity is offered by testing. Most people who don't develop diabetes until they are teenagers don't get an immune attack until they are 5 or 6.
He hopes to treat people earlier as soon as possible. The F.D.A. had previously objected to treating before the disease was obvious, asking if they could give an immunotherapy if they were normal. The doctor said that.
He said that the immune system tells a different story.
According to the usual definition of the disease, they do have diabetes. It hasn't been revealed yet. They need help saving their cells.
The doctor is cautious. The treatment may not work if the person's pancreas is not being attacked.
He said it was difficult to stop something that wasn't happening.
Dr. Herold and Dr. Bluestone wonder if a second round of treatment could make a difference.
The treatment that was used in the trial should be used to help younger patients. It is approved for patients under the age of 8. He said that the disease affects a lot of young patients.
There is an immediate challenge for diabetes experts because he and others are excited about the possibility of some day preventing the disease completely.
Finding the potential patients is the most important thing at the moment.
All Rights Reserved © 2024
